IMPG2: A Potential Drug Target for Cancer and Other Diseases (G50939)

Target Name: IMPG2

NCBI ID: G50939

IMPG2

IMPG2: A Potential Drug Target for Cancer and Other Diseases

IMPG2 (Immunomodulatory Proteomics Group 2) is a protein that is expressed in various tissues of the human body. It is a member of the IMP family, which includes proteins that play a crucial role in the immune response. The IMP family has been identified as a potential drug target in the treatment of various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

IMPG2: Structure and Function

IMPG2 is a 21-kDa protein that is expressed in various tissues of the human body, including the spleen, thymus, spleen lymphocytes, peripheral blood T cells, and the placenta. It is characterized by a unique structure that consists of a long amino acid sequence that is predominantly alpha-helices and a short carboxylic acid tail.

The N-terminus of IMPG2 contains a characteristic Rossmann-fold, which is a conserved structural motif that is involved in protein-protein interactions. The Rossmann-fold is a structural motif that is composed of a specific arrangement of amino acids that are involved in the formation of a尾-sheet. This motif is thought to play a role in the stability and function of the protein.

The C-terminus of IMPG2 contains a single amino acid residue, which is a glutamic acid. This residue is known as Glu-192 and is involved in the protein's stability.

Functional Analysis of IMPG2

IMPG2 is involved in the immune response by regulating the production of T cells. T cells are a crucial immune cell that play a role in protecting the body against infection and disease. They are produced in the bone marrow and T-cell loci, and their development and function are regulated by various signaling pathways.

IMPG2 is involved in the regulation of T cell development by the T-cell receptor (TCR) signaling pathway. The TCR is a transmembrane protein that is involved in the recognition of antigens by T cells. The TCR is composed of a variable region and a constant region, and it is expressed in the T cells.

IMPG2 is known to be a negative regulator of TCR signaling. This means that it works to prevent the activity of the TCR and to regulate the production of T cells. It does this by interacting with the TCR and by modulating the activity of downstream signaling pathways.

IMPG2 has been shown to play a role in the regulation of T cell costimulation. Costimulation refers to the process by which T cells become co-stimulated by different antigens. This process is important for the regulation of T cell responses and is critical for the development of immune tolerance.

IMPG2 has also been shown to play a role in the regulation of T cell survival. T cells are a vital part of the immune system and are involved in protecting the body against infection and disease. They are regulated by various signaling pathways, including the T-cell receptor (TCR) signaling pathway.

IMPG2 has been shown to play a role in the regulation of T cell receptor (TCR) signaling pathway. The TCR is a transmembrane protein that is involved in the recognition of antigens by T cells. The TCR is composed of a variable region and a constant region, and it is expressed in the T cells.

IMPG2 is known to be a negative regulator of TCR signaling. This means that it works to prevent the activity of the TCR and to regulate the production

Protein Name: Interphotoreceptor Matrix Proteoglycan 2

Functions: Chondroitin sulfate- and hyaluronan-binding proteoglycan involved in the organization of interphotoreceptor matrix; may participate in the maturation and maintenance of the light-sensitive photoreceptor outer segment. Binds heparin

The "IMPG2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IMPG2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets